Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1CNS 1

Conditions

Venous Thromboembolism 16Venous Thrombosis 10Pulmonary Embolism 9Neoplasms 7Thrombosis 2Thrombocytopenia 1Pancreatic Neoplasms 1Obesity 1Neoplasm Metastasis 1Mesenteric Ischemia 1Lung Neoplasms 1Intracranial Thrombosis 1Glioma 1Gastrointestinal Neoplasms 1Brain Neoplasms 1

Interventions

apixaban 1Temozolomide 1Rivaroxaban 1Radiotherapy 1Long-Term Synaptic Depression 1Dalteparin 1Comparative Genomic Hybridization 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Dalteparin × Classical hematology × Clear all
NCT00135876 2007-04-27

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

Ontario Clinical Oncology Group (OCOG)

Phase 3 Completed
512 enrolled
CNSClassical hematology

Brain Neoplasms, Glioma, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡